Nothing Special   »   [go: up one dir, main page]
create a website
How Does Cost-Sharing Affect Drug Purchases? Insurance Regimes in the Private Market for Prescription Drugs. (2004). Dor, Avi ; Encinosa, William .
In: NBER Working Papers.
RePEc:nbr:nberwo:10738.

Full description at Econpapers || Download paper

Cited: 9

Citations received by this document

Cites: 30

References cited by this document

Cocites: 54

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. Progress and compliance in alcohol abuse treatment. (2010). Ma, Ching-to ; Lu, Mingshan ; Lien, Hsienming ; McGuire, Thomas G..
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:29:y:2010:i:2:p:213-225.

    Full description at Econpapers || Download paper

  2. Value-based insurance design in medicare. (2009). Encinosa, William.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:7:y:2009:i:3:p:149-154.

    Full description at Econpapers || Download paper

  3. The demand for statin: the effect of copay on utilization and compliance. (2008). Patel, Bimal V. ; Thiebaud, Patrick ; Nichol, Michael B..
    In: Health Economics.
    RePEc:wly:hlthec:v:17:y:2008:i:1:p:83-97.

    Full description at Econpapers || Download paper

  4. Is American Health Care Uniquely Inefficient?. (2008). Skinner, Jonathan ; Garber, Alan M..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:14257.

    Full description at Econpapers || Download paper

  5. Organizational Fragmentation and Care Quality in the U.S. Health Care System. (2008). Rebitzer, James ; Taylor, Lowell J. ; Cebul, Randall D. ; Votruba, Mark.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:14212.

    Full description at Econpapers || Download paper

  6. Organizational Fragmentation and Care Quality in the U.S. Healthcare System. (2008). Rebitzer, James ; Cebul, Randall D. ; Votruba, Mark E. ; Taylor, Lowell J..
    In: Journal of Economic Perspectives.
    RePEc:aea:jecper:v:22:y:2008:i:4:p:93-113.

    Full description at Econpapers || Download paper

  7. Is American Health Care Uniquely Inefficient?. (2008). Skinner, Jonathan ; Garber, Alan M..
    In: Journal of Economic Perspectives.
    RePEc:aea:jecper:v:22:y:2008:i:4:p:27-50.

    Full description at Econpapers || Download paper

  8. Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits. (2006). Vogt, William ; Gaynor, Martin ; Li, Jian.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:12758.

    Full description at Econpapers || Download paper

  9. Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits. (2006). Vogt, William ; Gaynor, Martin ; Li, Jian.
    In: The Centre for Market and Public Organisation.
    RePEc:bri:cmpowp:07/166.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Breyer, F., P. Zweifel, and M. Kifmann. 2003. Gesundheitsokonomie. 4th edition, Springer: Berlin.
    Paper not yet in RePEc: Add citation now
  2. Bymark, L., and K. Waite. 2001. Prescription Drug Use and Expenditures in California: Key Trends and Drivers. California HealthCare Foundation: Oakland, CA.
    Paper not yet in RePEc: Add citation now
  3. Chernew, M., W. Encinosa, and R.Hirth. 2000. Optimal Health Insurance: The Case of Multiple Treatment Options. Journal of Health Economics 19 (2000), 585-609.
    Paper not yet in RePEc: Add citation now
  4. Cohen FJ, CA Neslusan, JE Conklin, and X. Song. 2003. Recent Hyperglycemic Trends for U.S Privately Insured Patients With Type 2 Diabetes. Diabetes Care 26:1847-1851.
    Paper not yet in RePEc: Add citation now

  5. Crown, W.H, Brendt, E.R., Baser, O. et al. 2003. Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter? NBER Working Paper 10062: Cambridge MA.

  6. Dezii C.M. 2000. Medication Noncompliance: What is the Problem? Managed Care 9(9), 12-7.
    Paper not yet in RePEc: Add citation now
  7. Elixhauser, A., C. Steiner, D. Harris, and R. Coffey. 1988. Comorbidity measures for use with administrative data. Medical Care 36:1, 8-27.
    Paper not yet in RePEc: Add citation now

  8. Ellison, SF., I. Cockburn, Z. Griliches and J. Hausman, 1997. Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. Rand Journal of Economics 28:3, 426-446.

  9. Encinosa, W, 200., Pharmacy Benefit Design Options Available to Employers. Expert Review of Pharmacoeconomics and Outcomes Research 2(4):389396, 2002.
    Paper not yet in RePEc: Add citation now
  10. Fuhrmans, V. 2004. A Radical Prescription. Wall Street Journal May, 10, 2004. pp R3-R4.
    Paper not yet in RePEc: Add citation now
  11. Gilman, K., M. Laouri, S. Wade, and S. Isonaka. 2003. Analysis of Medication Use Patterns: Apparent Overuse of Antibiotics and Underuse of Prescription Drugs for Asthma, Depression, and CHF. Journal of Managed Care Pharmacy 9:3, 232-237.
    Paper not yet in RePEc: Add citation now
  12. Goldman, D. et al. 2004. Pharmacy Benefits and the Use of Drugs by the Chronically Ill. Journal of the American Medical Association 291:19, 2344-2350.
    Paper not yet in RePEc: Add citation now
  13. Hughes DA, Bagust a, Haycox et al. , 2001. Accounting for Non-Compliance in Pharmacoeconomic Evaluations. Pharmacoecomics 19(12): 1185-97.
    Paper not yet in RePEc: Add citation now
  14. Huskamp, H., et al. 2003. The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending. New England Journal of Medicine 349:23, 2224-2232.
    Paper not yet in RePEc: Add citation now
  15. Inzucchi, S. 2002. Oral Antihyperglycemic Therapy for Type 2 Diabetes. Journal of the American Medical Association 287:3, 360-372.
    Paper not yet in RePEc: Add citation now
  16. Joyce, GF, JJ Escarce, MD Solomon, DP Goldman. 2002. Employer Drug Benefit Plans and Spending On Prescription Drugs. Journal of the American Medical Association 288:4, 1733-1739.
    Paper not yet in RePEc: Add citation now
  17. Karter, AJ. et al. 2003. Out-of-Pocket Costs and Diabetes Prevention Services. Diabetes Care 26:8, 2294-2299.
    Paper not yet in RePEc: Add citation now
  18. Leatherman, S., and D. McCarthy. 2002. Quality of Health Care in the United Sates: A Chartbook. April, 2002. The Commonwealth Fund: New York, NY.
    Paper not yet in RePEc: Add citation now

  19. Levy, H., and H. Markowitz, 1979. Approximating expected utility by a function of mean and variance. American Economic Review June 1979.

  20. Liang, S. K.Phillips, S. Tye, et al. 2004. Does patient Cost Sharing Matter? Its Impact on Recommended versus Controversial Cancer Screening Services. American Journal of Managed Care 10:2, 99-107.
    Paper not yet in RePEc: Add citation now

  21. Manning, WG, J.P. Newhouse, N. Duan, E.B. Keeler, A. Leibowitz, and M. S. Marquis. 1987. Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment. American Economic Review 77:251277. Meyer, J. 1987. Two-moment decision models with expected utility maximization, American Economic Review vol 77, 421-450.

  22. McDonald K, Romano P, Geppert J, et al. 2002. Measures of Patient Safety Based on Hospital Administrative Data-The Patient Safety Indicators. Technical Review 5. AHRQ Publication No. 02-0038. Agency for Healthcare Research and Quality: Rockville, MD.
    Paper not yet in RePEc: Add citation now
  23. National Healthcare Quality Report 2003. Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services: Rockville, MD.
    Paper not yet in RePEc: Add citation now
  24. Newhouse, J.P. and the Insurance Experiment Group. 1993. Free for All? Lessons from the RAND Health Insurance Experiment. Cambridge: Harvard University Press.
    Paper not yet in RePEc: Add citation now

  25. Pauly, M V. 1974.Overinsurance and the public provision of insurance: the role of moral hazard and adverse selection. Quarterly Journal of Economics 88:1, 44-62.

  26. Ridley D. 2004. Payments, Promotion, and the Purple Pill. Fuqua School of Business, Duke University, Working Paper.

  27. Thomas CP, SS Wallack, S. Lee, and GA Ritter. 2002. Impact of Health Plan Design and Management on Retirees Prescription Drug Use and Spending. Health Affairs Dec 2002 v21: w408-w409.
    Paper not yet in RePEc: Add citation now
  28. Wagner, EH, et al. 2001. Effect of Improved Glycemic Control on Health Care Costs and Utilization. Journal of the American Medical Association 285:2, 182-189.
    Paper not yet in RePEc: Add citation now
  29. Woellert, L. 2002. Soon We Will All Be Paying More for Prescription Drugs. Business Week, May 6.
    Paper not yet in RePEc: Add citation now
  30. Zweifel, P., 1995. Bonus Options in Health Insurance. Kluwer: London.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. .

    Full description at Econpapers || Download paper

  2. An Empirical Investigation into Physician Preferences in Drug Prescription: An Integrated Methodology of AHP and QFD. (2016). Elahi, Farzana ; Chowdhury, Nazreen ; Haque, Mahbubul ; Ahmed, Shamsad .
    In: International Journal of Marketing Studies.
    RePEc:ibn:ijmsjn:v:8:y:2016:i:5:p:81-89.

    Full description at Econpapers || Download paper

  3. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?. (2015). Granlund, David ; Koksal-Ayhan, Miyase .
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:16:y:2015:i:9:p:969-983.

    Full description at Econpapers || Download paper

  4. Competition and R&D Financing Decisions: Theory and Evidence from the Biopharmaceutical Industry. (2015). Lo, Andrew ; Thakor, Richard T..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:20903.

    Full description at Econpapers || Download paper

  5. The welfare impact of parallel imports: A structural approach applied to the German market for oral antidiabetics. (2014). Suppliet, Moritz ; Herr, Annika ; Duso, Tomaso.
    In: Annual Conference 2014 (Hamburg): Evidence-based Economic Policy.
    RePEc:zbw:vfsc14:100298.

    Full description at Econpapers || Download paper

  6. Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals. (2014). Xu, Judy ; Wu, Jiuhong ; Liu, Gordon.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:32:y:2014:i:3:p:293-303.

    Full description at Econpapers || Download paper

  7. Antibiotic consumption and the role of dispensing physicians. (2014). Masiero, Giuliano ; Filippini, Massimo ; Heimsch, F..
    In: Regional Science and Urban Economics.
    RePEc:eee:regeco:v:49:y:2014:i:c:p:242-251.

    Full description at Econpapers || Download paper

  8. The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-Diabetics. (2014). Suppliet, Moritz ; Herr, Annika ; Duso, Tomaso.
    In: Discussion Papers of DIW Berlin.
    RePEc:diw:diwwpp:dp1373.

    Full description at Econpapers || Download paper

  9. Pharmaceutical Followers. (2013). Ridley, David ; Ellickson, Paul ; Landry, Peter ; Arcidiacono, Peter .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:19522.

    Full description at Econpapers || Download paper

  10. Tarif forfaitaire de responsabilité : quels impacts sur le pharmacien ?. (2013). granier, laurent ; Franc, Carine ; Trinquard, Sebastien .
    In: Working Papers.
    RePEc:gat:wpaper:1309.

    Full description at Econpapers || Download paper

  11. Pharmaceutical followers. (2013). Ridley, David ; Landry, Peter ; Arcidiacono, Peter ; Ellickson, Paul B..
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:31:y:2013:i:5:p:538-553.

    Full description at Econpapers || Download paper

  12. Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector. (2013). Hostenkamp, Gisela .
    In: Health Policy.
    RePEc:eee:hepoli:v:111:y:2013:i:1:p:68-77.

    Full description at Econpapers || Download paper

  13. Regulation and competition in the Taiwanese pharmaceutical market under national health insurance. (2012). Hsieh, Chee-Ruey ; Yang, Yea-Huei Kao ; Liu, Ya-Ming .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:31:y:2012:i:3:p:471-483.

    Full description at Econpapers || Download paper

  14. Physician Agency and Adoption of Generic Pharmaceuticals. (2012). Iizuka, Toshiaki.
    In: American Economic Review.
    RePEc:aea:aecrev:v:102:y:2012:i:6:p:2826-58.

    Full description at Econpapers || Download paper

  15. Generic drugs in Spain: price competition vs. moral hazard. (2011). Moreno-Torres, Ivan .
    In: Working Papers.
    RePEc:xrp:wpaper:xreap2011-04.

    Full description at Econpapers || Download paper

  16. Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry. (2011). Higgins, Matthew ; Chatterjee, Chirantan ; Branstetter, Lee G..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:17188.

    Full description at Econpapers || Download paper

  17. Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?. (2011). Granlund, David ; Koksal, Miyase Yesim .
    In: HUI Working Papers.
    RePEc:hhs:huiwps:0049.

    Full description at Econpapers || Download paper

  18. Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals. (2011). Granlund, David ; Koksal, Miyase Yesim .
    In: Working Papers in Economics.
    RePEc:hhs:gunwpe:0496.

    Full description at Econpapers || Download paper

  19. Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment. (2011). Straume, Odd Rune ; Brekke, Kurt ; Holmas, Tor Helge .
    In: Journal of Public Economics.
    RePEc:eee:pubeco:v:95:y:2011:i:7:p:624-638.

    Full description at Econpapers || Download paper

  20. Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration. (2011). Ellison, Glenn.
    In: American Economic Journal: Microeconomics.
    RePEc:aea:aejmic:v:3:y:2011:i:1:p:1-36.

    Full description at Econpapers || Download paper

  21. Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes. (2010). Huang, Weng-Foung ; Chen, Pei-Fen ; Kuo, Ken ; Shih, Hsin-Wei ; Lee, Yue-Chune ; Wen, Yu-Wen ; Tsai, Yi-Wen.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:11:y:2010:i:3:p:279-290.

    Full description at Econpapers || Download paper

  22. Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. (2010). Ching, Andrew.
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:28:y:2010:i:6:p:619-638.

    Full description at Econpapers || Download paper

  23. Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy. (2010). Cockburn, Iain ; Stern, Scott.
    In: Capitalism and Society.
    RePEc:bpj:capsoc:v:5:y:2010:i:1:n:1.

    Full description at Econpapers || Download paper

  24. How Does Cost‐Sharing Affect Drug Purchases? Insurance Regimes in the Private Market for Prescription Drugs. (2010). Encinosa, William ; Dor, Avi.
    In: Journal of Economics & Management Strategy.
    RePEc:bla:jemstr:v:19:y:2010:i:3:p:545-574.

    Full description at Econpapers || Download paper

  25. The influence of managed care on generic prescribing rates: an analysis of HMO physicians. (2009). Rice, Jennifer .
    In: Applied Economics.
    RePEc:taf:applec:v:43:y:2009:i:7:p:787-796.

    Full description at Econpapers || Download paper

  26. Physician dispensing and antibiotic prescriptions. (2009). Masiero, Giuliano ; Filippini, Massimo ; Moschetti, Karine .
    In: Quaderni della facoltà di Scienze economiche dell'Università di Lugano.
    RePEc:lug:wpaper:0908.

    Full description at Econpapers || Download paper

  27. Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?. (2009). Grasdal, Astrid ; Brekke, Kurt ; Holms, Tor Helge.
    In: European Economic Review.
    RePEc:eee:eecrev:v:53:y:2009:i:2:p:170-185.

    Full description at Econpapers || Download paper

  28. Regional consumption of antibiotics: A demand system approach. (2009). Masiero, Giuliano ; Filippini, Massimo ; Moschetti, K..
    In: Economic Modelling.
    RePEc:eee:ecmode:v:26:y:2009:i:6:p:1389-1397.

    Full description at Econpapers || Download paper

  29. Generic Entry, Reformulations and Promotion of SSRIs in the US. (2008). Donohue, Julie ; Huskamp, Haiden ; Berndt, Ernst ; Koss, Catherine ; Frank, Richard.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:26:y:2008:i:7:p:603-616.

    Full description at Econpapers || Download paper

  30. Generic entry, price competition, and market segmentation in the prescription drug market. (2008). Regan, Tracy.
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:26:y:2008:i:4:p:930-948.

    Full description at Econpapers || Download paper

  31. Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration. (2007). Ellison, Glenn.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:13069.

    Full description at Econpapers || Download paper

  32. Characteristics of demand for antibiotics in primary care: an almost ideal demand system approach. (2007). Masiero, Giuliano ; Filippini, Massimo ; Moschetti, Karine .
    In: Quaderni della facoltà di Scienze economiche dell'Università di Lugano.
    RePEc:lug:wpaper:0701.

    Full description at Econpapers || Download paper

  33. Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?. (2007). Grasdal, Astrid ; Brekke, Kurt ; Holms, Tor Helge.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_2059.

    Full description at Econpapers || Download paper

  34. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: Evidence from Switzerland. (2006). Masiero, Giuliano ; Filippini, Massimo ; Moschetti, Karine .
    In: Health Policy.
    RePEc:eee:hepoli:v:78:y:2006:i:1:p:77-92.

    Full description at Econpapers || Download paper

  35. Drug utilization studies and data registries in primary care. (2005). Ortun, Vicente ; Cabaas, Anselmo Lopez ; Jose Antonio Diaz Berenguer, ; Santana, Fayna lamo ; Lopez-Valcarcel, Beatriz Gonzalez ; Mora, Antonio Cabeza.
    In: Economics Working Papers.
    RePEc:upf:upfgen:809.

    Full description at Econpapers || Download paper

  36. How Does Cost-Sharing Affect Drug Purchases? Insurance Regimes in the Private Market for Prescription Drugs. (2004). Dor, Avi ; Encinosa, William .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:10738.

    Full description at Econpapers || Download paper

  37. An empirical model of learning and patient spillovers in new drug entry. (2004). Shum, Matthew ; Coscelli, Andrea .
    In: Journal of Econometrics.
    RePEc:eee:econom:v:122:y:2004:i:2:p:213-246.

    Full description at Econpapers || Download paper

  38. POTENTIAL IMPACTS OF PHARMACEUTICAL USES OF TRANSGENIC TOBACCO: THE CASE OF HUMAN SERUM ALBUMIN (HSA). (2004). Norton, George ; Mills, Bradford ; Kostandini, Genti.
    In: 2004 Annual meeting, August 1-4, Denver, CO.
    RePEc:ags:aaea04:20289.

    Full description at Econpapers || Download paper

  39. Deadweight loss of bacterial resistance due to overtreatment. (2003). Elbasha, Elamin H..
    In: Health Economics.
    RePEc:wly:hlthec:v:12:y:2003:i:2:p:125-138.

    Full description at Econpapers || Download paper

  40. Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India. (2003). Barwick, Panle ; Goldberg, Pinelopi ; Jia, Panle ; Chaudhuri, Shubham .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:10159.

    Full description at Econpapers || Download paper

  41. Stuck in the Middle: Welfare Effects of the European Pharmaceutical Markets Incomplete Integration and a Possible Remedy. (2002). Kotzian, Peter .
    In: MZES Working Papers.
    RePEc:erp:mzesxx:p0031.

    Full description at Econpapers || Download paper

  42. Do Pharmaceutical Prices Respond to Insurance?. (2000). Pavcnik, Nina.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:7865.

    Full description at Econpapers || Download paper

  43. Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. (2000). Pindyck, Robert ; Berndt, Ernst R. ; Azoulay, Pierre.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:7772.

    Full description at Econpapers || Download paper

  44. Cross-national price differences for pharmaceuticals: how large, and why?. (2000). Danzon, Patricia ; Chao, Li-Wei .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:19:y:2000:i:2:p:159-195.

    Full description at Econpapers || Download paper

  45. Generic take-up in the pharmaceutical market following patent expiry: A multi-country study. (2000). Hudson, John.
    In: International Review of Law and Economics.
    RePEc:eee:irlaec:v:20:y:2000:i:2:p:205-221.

    Full description at Econpapers || Download paper

  46. Dynamic Equilibrium in the US Prescription Drug Market After Patent Expiration. (2000). Ching, Andrew.
    In: Econometric Society World Congress 2000 Contributed Papers.
    RePEc:ecm:wc2000:1242.

    Full description at Econpapers || Download paper

  47. A model for the Dutch pharmaceutical market. (1999). Canton, Erik ; Westerhout, ED.
    In: Health Economics.
    RePEc:wly:hlthec:v:8:y:1999:i:5:p:391-402.

    Full description at Econpapers || Download paper

  48. Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. (1999). Pindyck, Robert ; Berndt, Ernst R. ; Azoulay, Pierre.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:7024.

    Full description at Econpapers || Download paper

  49. Demand for Prescription Drugs: The Effects of Managed Care Pharmacy Benefits. (1998). Mortimer, Rika Onishi .
    In: HEW.
    RePEc:wpa:wuwphe:9802002.

    Full description at Econpapers || Download paper

  50. Money and Medicines: An Economic Analysis of Reference Pricing and Related Public-sector Cost-containment Systems for Pharmaceuticals with Special Reference to New Zealand, by Alan Woodfield, John Fou. (1998). Evans, Lew ; Quigley, Neil .
    In: Working Paper Series.
    RePEc:vuw:vuwcsr:3941.

    Full description at Econpapers || Download paper

  51. Book reviews. (1998). Evans, Lew ; Bano, Sayeeda ; Rad, Alireza Tourani ; Quigley, Neil ; Devlin, Nancy ; TouraniRad, Alireza .
    In: New Zealand Economic Papers.
    RePEc:taf:nzecpp:v:32:y:1998:i:1:p:83-103.

    Full description at Econpapers || Download paper

  52. Empirical Implications of Physician Authority in Pharmaceutical Decisionmaking. (1998). Trajtenberg, Manuel ; Stern, Scott.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:6851.

    Full description at Econpapers || Download paper

  53. Network effects and diffusion in pharmaceutical markets : antiulcer drugs. (1998). Pindyck, Robert ; Berndt, Ernst R..
    In: Working papers.
    RePEc:mit:sloanp:2744.

    Full description at Econpapers || Download paper

  54. Too much cocited documents. This list is not complete

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2024-12-15 22:56:14 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.